December 19, 2007
Framingham Drug Co. Adds Cancer Expert To Board
By Matthew L. Brown
Framingham-based GI Co. Inc. , a privately held developer of gastrointestinal therapeutics, expanded its scientific advisory board with the appointment of Douglas E. Peterson.
The company said Peterson, who works at the U.S. Food and Drug Administration, "is recognized as a thought leader in the field of oral and gastrointestinal mucosal injury that occurs secondary to high-dose cancer therapies."
The GI Co. has a clinical candidate drug being developed to treat oral mucositis, a common, debilitating complication resulting from high-dose chemotherapy and/or radiotherapy.
The advisory board is led by company co-founders Daniel K. Podolsky, a professor of medicine and chief of gastroenterology at Massachusetts General Hospital, Harvard Medical School and chief academic officer of Partners Healthcare and Chung Owyang, professor in gastroenterology and chief of the department of gastrointestinal disease at the University of Michigan.
The company said Peterson, who works at the U.S. Food and Drug Administration, "is recognized as a thought leader in the field of oral and gastrointestinal mucosal injury that occurs secondary to high-dose cancer therapies."
The GI Co. has a clinical candidate drug being developed to treat oral mucositis, a common, debilitating complication resulting from high-dose chemotherapy and/or radiotherapy.
The advisory board is led by company co-founders Daniel K. Podolsky, a professor of medicine and chief of gastroenterology at Massachusetts General Hospital, Harvard Medical School and chief academic officer of Partners Healthcare and Chung Owyang, professor in gastroenterology and chief of the department of gastrointestinal disease at the University of Michigan.
WBJ Web Partners
Most Recent
Most Recent
0 Comments